| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 17 | 2025 | 174 | 4.100 |
Why?
|
| Scleroderma, Systemic | 11 | 2025 | 123 | 2.010 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 7 | 2025 | 132 | 1.960 |
Why?
|
| Tomography, X-Ray Computed | 20 | 2025 | 2168 | 1.650 |
Why?
|
| Lung | 13 | 2025 | 1555 | 1.260 |
Why?
|
| Myositis | 3 | 2025 | 105 | 1.250 |
Why?
|
| Mycophenolic Acid | 7 | 2021 | 57 | 1.170 |
Why?
|
| Minimal Clinically Important Difference | 2 | 2025 | 9 | 1.070 |
Why?
|
| Pulmonary Fibrosis | 2 | 2025 | 112 | 1.060 |
Why?
|
| Pancreatic Neoplasms | 5 | 2025 | 728 | 1.030 |
Why?
|
| Immunosuppressive Agents | 9 | 2025 | 672 | 0.950 |
Why?
|
| Cyclophosphamide | 8 | 2025 | 428 | 0.940 |
Why?
|
| Cystadenoma, Serous | 1 | 2025 | 7 | 0.930 |
Why?
|
| Endocrine System Diseases | 1 | 2025 | 43 | 0.910 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2025 | 31 | 0.900 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2025 | 180 | 0.790 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2023 | 111 | 0.750 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 551 | 0.670 |
Why?
|
| Dyslipidemias | 1 | 2023 | 241 | 0.660 |
Why?
|
| Vital Capacity | 7 | 2025 | 85 | 0.640 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 1028 | 0.600 |
Why?
|
| Disease Progression | 9 | 2025 | 2222 | 0.560 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 112 | 0.520 |
Why?
|
| beta Catenin | 1 | 2018 | 225 | 0.510 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 1535 | 0.430 |
Why?
|
| Humans | 58 | 2025 | 131985 | 0.410 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1657 | 0.410 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2024 | 377 | 0.400 |
Why?
|
| Radiology | 2 | 2025 | 127 | 0.390 |
Why?
|
| Middle Aged | 21 | 2025 | 28976 | 0.390 |
Why?
|
| Aged | 14 | 2025 | 21415 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2025 | 293 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2091 | 0.330 |
Why?
|
| Female | 31 | 2025 | 70623 | 0.320 |
Why?
|
| Male | 30 | 2025 | 64910 | 0.320 |
Why?
|
| Adult | 15 | 2025 | 31547 | 0.290 |
Why?
|
| Respiratory-Gated Imaging Techniques | 2 | 2018 | 3 | 0.280 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 175 | 0.270 |
Why?
|
| Ovary | 2 | 2020 | 369 | 0.270 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 168 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 3830 | 0.260 |
Why?
|
| Pyridones | 2 | 2024 | 131 | 0.250 |
Why?
|
| Thrombosis | 2 | 2022 | 524 | 0.250 |
Why?
|
| Artificial Intelligence | 3 | 2025 | 298 | 0.250 |
Why?
|
| Image Enhancement | 2 | 2018 | 172 | 0.250 |
Why?
|
| Walk Test | 1 | 2025 | 29 | 0.240 |
Why?
|
| Pediatric Obesity | 2 | 2023 | 415 | 0.240 |
Why?
|
| Risk Factors | 7 | 2025 | 10941 | 0.240 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17391 | 0.230 |
Why?
|
| Specialty Boards | 1 | 2025 | 24 | 0.230 |
Why?
|
| Exercise Tolerance | 1 | 2025 | 90 | 0.230 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 53 | 0.230 |
Why?
|
| Endosonography | 1 | 2025 | 82 | 0.220 |
Why?
|
| Reproducibility of Results | 8 | 2025 | 3011 | 0.220 |
Why?
|
| Pamphlets | 1 | 2024 | 24 | 0.220 |
Why?
|
| Radiology, Interventional | 1 | 2024 | 35 | 0.210 |
Why?
|
| Abdominal Fat | 1 | 2024 | 24 | 0.210 |
Why?
|
| Emergencies | 1 | 2025 | 186 | 0.210 |
Why?
|
| Prognosis | 5 | 2025 | 5008 | 0.210 |
Why?
|
| Intra-Abdominal Fat | 1 | 2024 | 61 | 0.210 |
Why?
|
| Bacillus | 1 | 2023 | 37 | 0.200 |
Why?
|
| Thrombectomy | 2 | 2022 | 112 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2024 | 228 | 0.200 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2019 | 419 | 0.200 |
Why?
|
| Indoles | 1 | 2024 | 201 | 0.200 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 491 | 0.200 |
Why?
|
| Autoimmune Diseases | 1 | 2025 | 271 | 0.200 |
Why?
|
| Membrane Proteins | 3 | 2024 | 1610 | 0.190 |
Why?
|
| Registries | 3 | 2025 | 1579 | 0.190 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 38 | 0.190 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 308 | 0.190 |
Why?
|
| Educational Measurement | 1 | 2025 | 328 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 58 | 0.190 |
Why?
|
| Respiratory Function Tests | 5 | 2025 | 211 | 0.180 |
Why?
|
| Treatment Outcome | 10 | 2025 | 13019 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2025 | 2317 | 0.180 |
Why?
|
| Intracellular Membranes | 1 | 2021 | 59 | 0.170 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 93 | 0.170 |
Why?
|
| Immunohistochemistry | 1 | 2024 | 1694 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 465 | 0.170 |
Why?
|
| Abdomen | 1 | 2021 | 135 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2025 | 6569 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 39 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2021 | 93 | 0.160 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2020 | 66 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2020 | 238 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 167 | 0.160 |
Why?
|
| Social Environment | 2 | 2018 | 122 | 0.160 |
Why?
|
| Chemokines, CC | 1 | 2019 | 26 | 0.160 |
Why?
|
| Mucin-1 | 1 | 2019 | 35 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2021 | 333 | 0.160 |
Why?
|
| Self Concept | 2 | 2018 | 164 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 189 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1951 | 0.150 |
Why?
|
| Adolescent | 10 | 2023 | 20535 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 251 | 0.150 |
Why?
|
| Lysosomes | 1 | 2021 | 261 | 0.150 |
Why?
|
| Health Risk Behaviors | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cholangitis | 1 | 2018 | 40 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2023 | 3736 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2018 | 88 | 0.140 |
Why?
|
| Heterotaxy Syndrome | 1 | 2018 | 63 | 0.140 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2018 | 60 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2021 | 407 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2025 | 1068 | 0.140 |
Why?
|
| Osteosarcoma | 1 | 2020 | 262 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2022 | 384 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2024 | 553 | 0.140 |
Why?
|
| Global Health | 1 | 2023 | 644 | 0.140 |
Why?
|
| Cryosurgery | 1 | 2018 | 51 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2020 | 229 | 0.140 |
Why?
|
| Dasatinib | 1 | 2017 | 50 | 0.140 |
Why?
|
| Time Factors | 2 | 2025 | 6443 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2023 | 554 | 0.130 |
Why?
|
| Glioma | 1 | 2022 | 529 | 0.130 |
Why?
|
| Child | 10 | 2023 | 25762 | 0.130 |
Why?
|
| Radiometry | 1 | 2017 | 43 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 414 | 0.130 |
Why?
|
| Protein Transport | 1 | 2018 | 369 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 551 | 0.130 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2016 | 8 | 0.130 |
Why?
|
| Ferrosoferric Oxide | 1 | 2016 | 27 | 0.130 |
Why?
|
| Integrin beta Chains | 1 | 2016 | 9 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 462 | 0.120 |
Why?
|
| Body Composition | 1 | 2019 | 550 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 602 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 504 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2021 | 513 | 0.120 |
Why?
|
| Cough | 1 | 2016 | 96 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 444 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2140 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 518 | 0.120 |
Why?
|
| Infant, Newborn | 3 | 2025 | 8542 | 0.120 |
Why?
|
| Myocardium | 1 | 2020 | 907 | 0.120 |
Why?
|
| Biliary Atresia | 1 | 2018 | 206 | 0.120 |
Why?
|
| Cell Nucleus | 1 | 2018 | 587 | 0.120 |
Why?
|
| Attitude to Health | 1 | 2017 | 262 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2024 | 1658 | 0.120 |
Why?
|
| Schools | 1 | 2017 | 236 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 237 | 0.110 |
Why?
|
| Skin | 1 | 2017 | 527 | 0.110 |
Why?
|
| Social Support | 1 | 2017 | 387 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2018 | 519 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 232 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 589 | 0.100 |
Why?
|
| United States | 3 | 2024 | 11653 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 7100 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2507 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 625 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 472 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1342 | 0.100 |
Why?
|
| Potassium Channels | 1 | 2014 | 160 | 0.100 |
Why?
|
| Contrast Media | 3 | 2024 | 507 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 1378 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 787 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4683 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 214 | 0.090 |
Why?
|
| Obesity | 1 | 2024 | 2394 | 0.090 |
Why?
|
| Quality of Life | 2 | 2023 | 2158 | 0.090 |
Why?
|
| Premenopause | 2 | 2020 | 40 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2021 | 247 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2021 | 146 | 0.080 |
Why?
|
| Algorithms | 3 | 2024 | 1721 | 0.080 |
Why?
|
| Equipment Design | 2 | 2022 | 602 | 0.080 |
Why?
|
| Monte Carlo Method | 2 | 2021 | 102 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2438 | 0.080 |
Why?
|
| Mutation | 3 | 2018 | 6227 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1131 | 0.070 |
Why?
|
| Young Adult | 5 | 2020 | 9952 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1499 | 0.070 |
Why?
|
| Artifacts | 2 | 2018 | 114 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 3089 | 0.060 |
Why?
|
| Epilepsy | 1 | 2014 | 889 | 0.060 |
Why?
|
| Abatacept | 1 | 2025 | 27 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 1861 | 0.060 |
Why?
|
| Semantics | 1 | 2024 | 27 | 0.060 |
Why?
|
| Image-Guided Biopsy | 1 | 2024 | 44 | 0.050 |
Why?
|
| Lakes | 1 | 2024 | 4 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2024 | 114 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2024 | 46 | 0.050 |
Why?
|
| Biological Transport | 1 | 2024 | 348 | 0.050 |
Why?
|
| Quinolines | 1 | 2024 | 120 | 0.050 |
Why?
|
| Search Engine | 1 | 2023 | 11 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5412 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3678 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 2913 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3410 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 663 | 0.050 |
Why?
|
| Forecasting | 1 | 2024 | 371 | 0.050 |
Why?
|
| Family Relations | 1 | 2023 | 71 | 0.050 |
Why?
|
| Pancreatic Ducts | 1 | 2021 | 22 | 0.050 |
Why?
|
| Language | 1 | 2023 | 224 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 76 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2023 | 264 | 0.040 |
Why?
|
| Glycine | 1 | 2022 | 161 | 0.040 |
Why?
|
| Meglumine | 1 | 2020 | 16 | 0.040 |
Why?
|
| Overweight | 1 | 2024 | 383 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2021 | 149 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2021 | 133 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 118 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1672 | 0.040 |
Why?
|
| Pyridines | 1 | 2022 | 249 | 0.040 |
Why?
|
| Mucin-5B | 1 | 2020 | 13 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2024 | 335 | 0.040 |
Why?
|
| California | 1 | 2020 | 139 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 111 | 0.040 |
Why?
|
| Spirometry | 1 | 2020 | 75 | 0.040 |
Why?
|
| Breath Holding | 1 | 2019 | 8 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 391 | 0.040 |
Why?
|
| Body Fat Distribution | 1 | 2019 | 32 | 0.040 |
Why?
|
| Computer Graphics | 1 | 2019 | 39 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 123 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1045 | 0.040 |
Why?
|
| North America | 1 | 2018 | 265 | 0.040 |
Why?
|
| Mice | 3 | 2021 | 18461 | 0.040 |
Why?
|
| Animals | 4 | 2021 | 34789 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1441 | 0.030 |
Why?
|
| Friends | 1 | 2017 | 18 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2658 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1573 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3760 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 1 | 2016 | 20 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 4703 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 242 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 822 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 469 | 0.030 |
Why?
|
| Peer Group | 1 | 2017 | 121 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2016 | 57 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1079 | 0.030 |
Why?
|
| Perception | 1 | 2017 | 237 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 243 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3991 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 2444 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 713 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2015 | 93 | 0.030 |
Why?
|
| Minority Groups | 1 | 2017 | 249 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 174 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 239 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1284 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 303 | 0.030 |
Why?
|
| Students | 1 | 2017 | 263 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 1796 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 1647 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1181 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1246 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 421 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2014 | 11 | 0.030 |
Why?
|
| NAV1.2 Voltage-Gated Sodium Channel | 1 | 2014 | 8 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 540 | 0.030 |
Why?
|
| Uniparental Disomy | 1 | 2014 | 42 | 0.030 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2014 | 42 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1229 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 67 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 286 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2014 | 109 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 338 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 446 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 664 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 2056 | 0.020 |
Why?
|
| Infant | 2 | 2018 | 13047 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1743 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 596 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 4752 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 685 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2192 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2697 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 946 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5166 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 3406 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1828 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3351 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 14732 | 0.010 |
Why?
|